AI driven 10Q / 10K text analysis
Since there are always reasons when companies change the wording in their financial filings, being alerted to these changes allows investors to realise potential risk factors and opportunities before they are reflected in the market. Recent alerts include: 1) Akamai - ongoing competition, pricing pressure, DIY, alternative sourcing strategies. 2) Align - increased competition? Customs investigations? 3) Arista Networks - more benign competitive and market conditions. 4) Bruker - covenant concerns. 5) Celanese - greater than usual year-end destocking in Q4. 6) Jazz Pharmaceuticals - caution on ability to maintain or increase sales.
Edition: 224
- 14 November, 2025
Healthcare alpha generation
Healthcare
Channel Dynamics has built a strong record of HC alpha generation by leveraging deep channel checks with private company experts and providers. Over the past 12+ months, their calls have consistently delivered meaningful relative alpha from report release through earnings, ahead of major stock moves including: UnitedHealth (flagged negative MLR inflection and UNH exposure before disappointing earnings and stock collapse); DexCom (called negative inflection in DME performance before turning back positive on DME relationship improvements and G7 market share gains); Align (correctly predicted Q/Q shifts in clear aligner and capital equipment purchasing trends); Penumbra (called positive DVT market growth trends and PEN market share gains in DVT, PE and Neuro Segments); and Dentsply Sirona (flagged worsening product/vendor performance and further deterioration from tariff impacts).
Edition: 220
- 19 September, 2025
Healthcare
Abacus' 40-page initiation report finds the market is too bearish - 2022 is an anomaly. ALGN's business model and competitive position have not been impaired. Downgrades were part of the pandemic dislocation and management’s over-optimism. ALGN’s near monopoly position unlikely to change (the D2C model has basically failed and Abacus cannot see any way for it to be revived). Forecasts earnings to grow at a 30% CAGR from 2022-25 driven by a recovery in revenue growth and operating margins. Forward P/E is below historical average and low relative to peers; sees ~80% upside over next couple of years (TP $514).
Edition: 142
- 19 August, 2022